Raymond Taylor is vice president of global development and product team leader for antivirals at BioCryst Pharmaceuticals. BioCryst designs, optimizes, and develops novel small-molecule drugs that block key enzymes to treat rare diseases. Since joining BioCryst in 2007, Ray has been the drug development team leader for two antiviral small molecules discovered by BioCryst. Rapivab (peramivir for injection) is an antiviral for treating influenza. Rapivab was approved by the FDA in 2014 and is the only approved parenteral influenza antiviral. Galidesivir is a direct-acting broad-spectrum antiviral drug under investigation for the treatment of serious and life-threatening infections from highly pathogenic viruses. Galidesivir has shown efficacy in lethal rodent and NHP models of filovirus diseases (Marburg virus disease and Ebola virus disease), and rodent models of yellow fever, Zika, and Rift Valley fever. Prior to joining BioCryst, Ray worked for various pharmaceutical companies including, Merck KGAA, Astra Zeneca, and Merck & Co. in areas of clinical development, data management, project management, and information technology.